WO2002066636A2 - T cell receptor variants expressed in mesenchymal cells and uses thereof - Google Patents
T cell receptor variants expressed in mesenchymal cells and uses thereof Download PDFInfo
- Publication number
- WO2002066636A2 WO2002066636A2 PCT/IL2002/000130 IL0200130W WO02066636A2 WO 2002066636 A2 WO2002066636 A2 WO 2002066636A2 IL 0200130 W IL0200130 W IL 0200130W WO 02066636 A2 WO02066636 A2 WO 02066636A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- intronic
- gene sequence
- sequence coding
- seq
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 73
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 65
- 210000004027 cell Anatomy 0.000 title claims description 163
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 149
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 135
- 239000002299 complementary DNA Substances 0.000 claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 29
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 25
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 25
- 239000002157 polynucleotide Substances 0.000 claims abstract description 25
- 230000010261 cell growth Effects 0.000 claims abstract description 21
- 108020004705 Codon Proteins 0.000 claims abstract description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 18
- 229930182817 methionine Natural products 0.000 claims abstract description 18
- 238000005304 joining Methods 0.000 claims abstract description 16
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 210000005260 human cell Anatomy 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 230000029663 wound healing Effects 0.000 claims description 7
- 238000001890 transfection Methods 0.000 claims description 6
- 101150090724 3 gene Proteins 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 3
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 claims description 3
- 101150084750 1 gene Proteins 0.000 claims description 2
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101150008942 J gene Proteins 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 52
- 150000001413 amino acids Chemical group 0.000 abstract description 6
- 108020004999 messenger RNA Proteins 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 40
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 210000002536 stromal cell Anatomy 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 210000001185 bone marrow Anatomy 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000074 antisense oligonucleotide Substances 0.000 description 12
- 238000012230 antisense oligonucleotides Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 11
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004491 Antisense DNA Proteins 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003816 antisense DNA Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 210000004381 amniotic fluid Anatomy 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000018265 Virus Receptors Human genes 0.000 description 3
- 108010066342 Virus Receptors Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000004524 haematopoietic cell Anatomy 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000270725 Caiman Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- -1 ketomethylene Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 208000006971 mastocytoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000639 membranetropic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 101150083745 preT gene Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- GTJASUYQSYEAFD-NPRBSQQLSA-N 102643-50-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N)[C@@H](C)O)C1=CC=CC=C1 GTJASUYQSYEAFD-NPRBSQQLSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 102000015404 Amino Acid Receptors Human genes 0.000 description 1
- 108010025177 Amino Acid Receptors Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000011968 CXCR6 Receptors Human genes 0.000 description 1
- 108010061304 CXCR6 Receptors Proteins 0.000 description 1
- 102100021198 Chemerin-like receptor 2 Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100023416 G-protein coupled receptor 15 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000750094 Homo sapiens Chemerin-like receptor 2 Proteins 0.000 description 1
- 101000829794 Homo sapiens G-protein coupled receptor 15 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101710151833 Movement protein TGBp3 Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 108010050138 synthetic joining segment peptide Proteins 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to polynucleotide transcripts comprising intronic sequences of T cell receptor (TCR) genes expressed in mesenchymal cells, to antisense polynucleotides of these and uses thereof in the modulation of mesenchymal cell growth. It further relates to the novel proteins, or peptides encoded by these transcripts, and uses thereof.
- TCR T cell receptor
- MHC Major Histocompatibility Complex
- MHC-restricted T cells express heterodimeric surface protein receptors ( ⁇ TCR) that co-localize with up to five additional non-variant membrane receptors (Strominger, 1989; Abbas et al., 1994; Jameson et al., 1995).
- This TCR complex specifically binds processed peptide antigens associated with MHC molecules.
- the interactions of TCR with MHC bound peptides on various target cells may have consequences both in terms of T cell proliferation and in activation of effector mechanisms leading to target cell killing, graft rejection, and other biological effects.
- TCR ⁇ and ⁇ chain genes which are capable of being expressed as polypeptides, are normally present only in cells of the T lymphocyte lineage. These functional TCR genes are formed by somatic rearrangement of germline gene segments. Each TCR locus consists of variable (V), joining (J), and constant (C) region genes, and the ⁇ chain locus contains diversity (D) gene segments. In mice there are 20 to 30 N ⁇ gene segments that are located 5' of the two clusters of C and J segments. There is a single C ⁇ gene associated with a large 5' cluster of up to 50 different J segments and about 75 N ⁇ and J ⁇ exons, which includes the entire TCR ⁇ chain locus. During maturation of T cells in the thymus, the TCR segments are rearranged in a defined order, resulting in the formation of functional TCR and ⁇ genes in which N, D, J and C segments are in close proximity to each other.
- the ⁇ chain locus rearranges prior to the ⁇ locus.
- the primary transcripts contain noncoding intronic sequences between the NDJ and C genes, which are later spliced out.
- the functional T cell receptor is comprised of 2 polypeptides: the ⁇ chain is a 40 to 60 kD acidic glycoprotein, and the ⁇ chain is a 40 to 50 kD uncharged or basic glycoprotein.
- the V and C regions of ⁇ and ⁇ chains form intrachain disulfide bond loops, which might contribute to the formation of a tertiary structure and are present on the cell membrane.
- the C region contains the transmembrane domain and a short cytoplasmic tail thought to be too small to have intrinsic signal transducing properties.
- T cells express a series of incomplete transcripts of TCR ⁇ and ⁇ , that vary in size and structure. These transcripts may be out of frame or their sequence may contain many stop codons. In some cases mR ⁇ As encoding the constant region flanked by an upstream spliced J segment were identified. In one case such a transcript of human TCR ⁇ which contains an in-frame codon for methionine has been reported (Fagioli et al., 1991). However, no evidence for the existence of a protein encoded by these transcripts in T cells has been documented.
- TCR transcripts have also been reported in cell lineages other than T or B- lymphocytes.
- TCR ⁇ mR ⁇ A was identified in murine kidney (Madrenas et al., 1991; Madrenas et al., 1992; Madrenas et al., 1994).
- a recent study identified in epithelial tumor cells a partial TCR ⁇ chain mR ⁇ A, lacking the N region. This mR ⁇ A encodes a 7 kDa protein, TARP, which is translated from an alternate reading frame and is therefore not homologous to the TCR ⁇ protein (Essand et al., 1999; Wolfgang et al., 2000). No evidence for TCR ⁇ or TCR ⁇ transcripts or proteins was found in this study. It is therefore generally accepted that TCR ⁇ transcripts are not found outside of the lymphocyte lineage and that TCR protein expressed at the cell surface is a specific T cell trait.
- Mesenchymal cells play a central role in embryogenesis by directing organogenesis. In the adult organism, tissue remodeling, such as that occurring in wound healing, is initiated by mesenchymal fibroblasts. The study of regulation of hemopoiesis demonstrated that blood cell formation is locally regulated by stromal mesenchyme (Zipori, 1989; Zipori et al., 1989; Zipori, 1990; Weintroub et al., 1996).
- bone marrow-derived primary stroma as well as a variety of mesenchymal cells lines derived from primary bone marrow cultures exhibit the capacity to support hemopoiesis in vitro and, upon transplantation, promote the formation of bone and hemopoietically active tissue in vivo at the site of transplantation.
- the molecules that mediate the stromal activities have been shown to be a variety of cytokines and adhesion molecules.
- the molecules identified thus far cannot account for the wide spectrum of stromal cell functions and certainly do not explain stroma organization, stem cell renewal and other vital stromal functions.
- the present invention relates to novel polynucleotide transcripts and encoded proteins, which are short versions of ⁇ and ⁇ chains of the T cell receptor (TCR) as detailed herein below, and to uses of these molecules.
- TCR T cell receptor
- bone marrow derived stromal mesenchymal cells express unique truncated T cell receptor gene transcripts. Furthermore, these unique transcripts comprise intronic J sequences but lack variable
- the present invention relates, in one aspect, to a cDNA molecule encoded by a T cell receptor (TCR) gene in non-hemopoietic cells, particularly in stromal mesenchymal cells, said cDNA molecule lacking V region sequences and comprising a constant (C) domain and joining (J) region sequences, and a 5' intronic J sequence upstream to said J region sequence including an in-frame methionine codon.
- TCR T cell receptor
- novel polynucleotide sequences disclosed herein and the corresponding proteins, polypeptides or peptides encoded by these polynucleotide sequences may be derived from any mammalian species including human genetic material.
- the cDNA molecule is encoded by a mouse TCR ⁇ gene.
- the joining (J) gene sequence may be selected from, but is not limited to, J ⁇ 2.1 and J ⁇ 2.6.
- the joining (J) gene sequence may be J ⁇ 2.1 and said 5' intronic J sequence including an in-frame methionine codon encodes a peptide of the sequence MENNSNPGSCIEEGEERGRILGSPF L[SEQIDNO:l].
- the joining (J) gene sequence is J ⁇ 2.6 and said 5' intronic J sequence including an in-frame methionine codon codes for a peptide of the sequence MGEYLAEPRGFVCGVEPLC [SEQ ID NO:2].
- the cDNA molecule is encoded by a mouse TCR ⁇ gene.
- the joining (J) gene sequences are selected from, but not limited to, J ⁇ TA31, J ⁇ TA46, J ⁇ New05, J ⁇ S58, J ⁇ New06, J ⁇ NewO ⁇ , J ⁇ LB2A, J ⁇ DKl,andJ ⁇ TA39.
- the cDNA molecule comprises a 5' intronic J sequence including an in-frame methionine codon selected from the group consisting of:
- SHLVPETERAEGPGNFVEHDI [SEQ ID ⁇ O:8]; (vii) the intronic J ⁇ New06 gene sequence coding for the peptide: MYFTGRKVDEPSELGSGLELSYFH
- RAEGPGVFVEHDI [SEQ ID NO:9]; (viii) the intronic J ⁇ New06 gene sequence coding for the peptide: MISTSHGHFQEMQFSIWSFTVLQIS
- the novel intronic sequences and their corresponding peptides may be derived from human genetic material. Any known sequences, such as intronic sequences of the joining segment of human J ⁇ 2.3 gene known in tumor cells (Kimoto, 1998) are explicitly excluded from the claimed novel sequences.
- the cDNA molecule comprises a 5' intronic J sequence including an in-frame methionine codon consisting of the human intronic J ⁇ 2.3 gene sequence coding for the peptide MGLSAVGRTRAESGT AERAAPVFVLGLQAV[SEQIDNO:17].
- the cDNA molecule is encoded by a human TCR ⁇ gene.
- the joining (J) gene sequences are selected from, but not limited to, J ⁇ 2, J ⁇ 3, J ⁇ 6, J ⁇ 8, J ⁇ 9, J ⁇ ll, J ⁇ l3, J ⁇ l4, J ⁇ 24, J ⁇ 25, J ⁇ 31, J ⁇ 36, J ⁇ 40, J ⁇ 41 and J ⁇ 44.
- the cDNA molecule comprises a 5' intronic J sequence, including an in-frame methionine codon selected from group consisting of: 1) the intronic J ⁇ 2 gene sequence coding for an in-frame M
- the invention relates to antisense DNA molecules of any of the cDNA molecules of the invention described above.
- the invention further relates to expression vectors comprising the cDNA and antisense molecules of the invention, and to host cells, particularly mammalian cells, comprising said vectors.
- the host cells are transfected mesenchymal human cells.
- the cDNA of the invention can be used to transfect mesenchymal human cells for inducing mesenchymal cell growth.
- the invention relates to compositions comprising said transfected mesenchymal human cells for use in disorders requiring induction of mesenchymal cell growth, such as wound healing.
- the invention further relates to a method for inducing mesenchymal cell growth comprising the step of administering to a subject in need thereof transfected mesenchymal human cells comprising a cDNA molecule according to the invention, in an amount effective to induce mesenchymal cell growth.
- This method is preferably applicable for enhanced wound healing.
- the antisense DNA molecules of the invention can be used to transfect mesenchymal human cells for inhibiting or suppressing mesenchymal cell growth.
- the invention relates to compositions comprising said transfected mesenchymal human cells for use in disorders requiring inhibition or suppression of mesenchymal cell growth, such as in carcinomas.
- the invention further relates to a method for suppressing mesenchymal cell growth comprising the step of administering to a subject in need thereof an antisense DNA molecule of the invention and/or autologous transfected mesenchymal human cells comprising an antisense DNA molecule of the invention, in an amount effective to suppress mesenchymal cell growth, such as for suppression of carcinomas.
- the invention further relates to a polypeptide encoded by a polynucleotide of the invention.
- said polypeptide is a protein capable of being expressed in mesenchymal cells, either on the cell surface or intracellularly.
- the polynucleotide is encoded by the nucleotide sequence depicted in Fig.
- the invention still further relates to a synthetic peptide deduced from an intronic J sequence of a TCR.
- peptides derived from non-human animals include but are not limited to: (a)MENNSNPGSCIEEGEERGRILGSPFL [SEQ ID NO:l];
- LVPETERAEGPGVFVEHDI [SEQIDNO:ll]; (l)MWWGLILSASVKFLQRKEILC [SEQ ID NO:12]; (m)MVGADLCKGGWHCV [SEQ ID NO: 13];
- Examples of useful peptides according to the present invention derived from human sources include but are not limited to: i)MGLSANGRTRAESGTAERAAPNFNLGLQAN[SEQID
- the invention relates to an antibody that binds to a synthetic peptide having a sequence encoded by intronic sequences of the TCR genes.
- the antibodies bind to a synthetic peptide having the sequence LAEPRGFNCGVE [SEQ ID ⁇ O:37]. These antibodies are useful as markers of mesenchymal cells, for example for diagnostic purposes and for prognosis of cancer.
- Fig. 1 depicts the nucleotide sequence of the J mt J-C ⁇ 2 mRNA transcript of the stromal/mesenchymal cell line [SEQ ID NO: 38], MBA-13, and the deduced amino acid sequence encoded thereby [SEQ ID NO: 39].
- the cDNA products were obtained from reverse transcription (RT)-PCR analysis using TCR primers and sequenced.
- Figs. 2A-2F show flow cytometric analysis of J ⁇ m 7-C ⁇ 2 expression by mesenchymal cells.
- Mouse embryonic fibroblasts (MEF) (2E) and different MBA-13 cell strains (1-3; 2A-2C, respectively) were stained with preimmunized (histogram I) or immunized (histogram II) purified antibodies from rabbit serum.
- the rabbits were immunized with a synthetic segment of SEQ ID NO:2, namely SEQ ID NO:37, with the sequence LAEPRGFNCGVE.
- Fab FITC conjugated donkey anti-rabbit IgG Staining with second antibody only gave a histogram shown in histogram III.
- Fig. 3 shows RT-PCR analysis of the novel TCRC ⁇ 2 cDNA including an in- frame intronic J sequence designated J mt J-C ⁇ 2, obtained from MBA-13 mesenchymal cell line and fetal primary cell cultures.
- the cDNA was obtained from total RNA extracted from mouse embryonic fibroblast and different MBA-13 cell strains (1-3).
- RT-PCR was performed using the following sense pairs: exonic J ⁇ 2.6: 5'-CTATGAACAGTACTTCGGTC-3 '; or intronic J ⁇ 2.6: 5'-ATGGGAGAATACCTCGCTG-3'; or 5 -CCCTAAATGGGAGAATACC; and antisense primer C ⁇ 3: 5'-CATCCTATCATCAGGGGGTTCTGTCTGCAA-3'. Products of 465 bp and 524 bp were produced, respectively.
- Fig. 4 depicts sequences of all possible versions of mouse TCR ⁇ containing an intronic 5' end including an in-frame Met codon as collected from available data bases: the intronic J ⁇ sequences J ⁇ 2.1 and J ⁇ 2.6, and the intronic J ⁇ sequences J ⁇ TA31, J ⁇ TA46, J ⁇ New05, J ⁇ S58, J ⁇ New06, J ⁇ New08, J ⁇ LB2A, J ⁇ DKl and J ⁇ TA39.
- Fig. 5 depicts sequences of all possible versions of the human TCR ⁇ containing an intronic 5' end including an in-frame Met codon as collected from available data bases: the intronic J ⁇ sequence J ⁇ 2.3, and the intronic J ⁇ sequences J ⁇ 2, J ⁇ 3, J ⁇ 6, J ⁇ 8, J ⁇ 9, J ⁇ l 1, J ⁇ l3, J ⁇ l4, J ⁇ 24, J ⁇ 25, J ⁇ 31, J ⁇ 36, J ⁇ 40, J ⁇ 41 and J ⁇ 44.
- Fig. 6 shows determination of generation time of different clones of MBA-13 cell line.
- Eight individual clones were studied by PCR for expression of M-TCR (TCR ⁇ J int -J 2 .eC). Out of those, four were found to be negative (M-TCR " clones E4, C6, Gl, B7) and four were found to be positive (M-TCR + clones C4, D10, BIO, BI). Cells were seeded at different concentrations (10 3 , 5x10 3 and 10 4 /ml) and cell growth was determined after 44 - 46 hours. The population generation time was calculated.
- Figs. 7A-7C show RT-PCR analysis of TCR expression in different cell lines and primary cell cultures.
- cDNA was obtained from total RNA extracted from different cell types, as described in the Materials and Methods section hereinafter, and RT-PCR was performed using the following primer pairs: C ⁇ l and C ⁇ 2 primers for TCRC ⁇ 2 produced a 410 bp product (Fig. 7A); C ⁇ l and Tm or C ⁇ l and C ⁇ 2 for TCRC ⁇ produced a 356 bp or 138 bp product, respectively (Figs. 7B and 7C).
- Figs. 8A-8D show mRNA expression of TCRC ⁇ (8A-8B), TCRC ⁇ (8C) and
- CD3 ⁇ (8D) mRNA transcripts Poly A+ mRNA, from mesenchymal (MBA-13, AC-6, NIH3T3, thymus and MEF), epithelial (1C8) and endothelial-adipocyte (14F1.1) cell lines, was Northern blotted as described in the Materials and Methods section hereinafter, and probed with the following probes: TCRC ⁇ , TCRC ⁇ and CD3 ⁇ .
- TCRC ⁇ For the TCRC ⁇ chain, thymus RNA exhibited 1.3 kb (full-length) and 1.0 kb (truncated) transcripts, while the mesenchymal MBA-13, AC-6 and MEF cells exhibited a 1.1 kb transcript (Figs. 8A and 8B).
- TCRC ⁇ chain thymus RNA and non-T cell lines exhibited a 1.6 kb transcript (Fig. 8C).
- thymus RNA exhibited a 1.5 kb transcript, while non-T cells showed a transcript whose size was slightly larger (Fig. 8D).
- Hybridization signals for TCRC ⁇ were quantitated by densitometric scanning, and the signal value of MBA-13 was 60 fold less than thymocytes.
- Fig. 9 shows flow cytometric analysis of CD3 ⁇ , TCR ⁇ and TCR ⁇ antigen expression by MBA-13 cells.
- MBA-13 cells were stained with FITC-conjugated TCR ⁇ , CD3 ⁇ and with PE-conjugated TCR ⁇ (solid line).
- solid line For intracellular staining, cells were fixed and stained with FITC-conjugated TCR ⁇ using the Cytoperm kit.
- cells stained with isotype-matched FITC-conjugated rat anti-mouse IgG were also prepared as negative controls (dotted line). The results of a single experiment are shown.
- TCR ⁇ antibody Flow cytometric analysis of MEF from wild type (solid black line) or from TCR " ⁇ mutant mice (***solid grey line) stained by the FITC-conjugated hamster anti-mouse TCR ⁇ H57-597 monoclonal antibodies. The dotted line indicates the isotype control.
- Fig. 11 Human TCR J ⁇ 2.3-C ⁇ . transcript cloned from cDNA of cord blood mononuclear cells and amniotic fluid cells. The cloned transcripts were sequenced and were found to be identical. The lines above the sequence indicate the boundaries of each segment. The predicted protein product is shown below the sequence. Bold font indicates an A to G transition that was found in both clones.
- Fig. 12 Expression of GFP-TCR J ⁇ 2.3-C ⁇ in 293T transfected cells. Western blot analysis. Each lane was loaded with lysate of 5x10 5 cells, GFP-TCR J ⁇ 2.3-C ⁇ was detected with Anti-GFP monoclonal antibody JL-8.
- Fig. 13 Reco binant mesenchymal TCR ⁇ (GFP-J int -J ⁇ 2.6-C) in a preTCR-like complex causes apoptotic cell death upon overexpression.
- A Immunofluorescence analysis of cells transfected with cDNA constructs encoding a fusion protein of J m *-J ⁇ 2.6-C linked to GFP, together with pT ⁇ HA vector.
- B Western blot analysis of extracts from 293T cells transfected with GFP-J int -J ⁇ 2.6-C together with HA-pT ⁇ (lane 1).
- GFP and HA vectors (lane 2), GFP vector and HA-pT ⁇ (lane 3), HA vector and GFP-ji n -J ⁇ 2.6-C (lane 4) and untransfected cells (lane 5). Immunoblotting was performed with an anti-GFP monoclonal antibody. The position of the fusion protein, GFP-J mt -J ⁇ 2.6-C is indicated (GFP-J int ) as is the position of GFP free protein (GFP). (C) Cell cycle flow cytometric analysis of 293T cells transfected with the indicated vectors.
- Fig. 14 Properties of individual clones of the MBA-13 cell line in which tumor formation of MBA-13 clones expressing high (D 10, B10, C4) or low (C6, B7) TCR ⁇ was examined following intradermal injection into nude CD1 mice at 10 6 cells per site.
- the present invention relates to new mRNA transcripts and proteins encoded by these transcripts which are short versions of ⁇ and ⁇ TCR as detailed and to uses of these molecules.
- RT-PCR reverse transcription polymerase chain reaction
- the MBA-13 mesenchymal stromal cell line derived from mouse bone marrow, was found to consistently express TCR ⁇ constant (C ⁇ ) region, while cDNA from a negative control tissue, i.e. liver, and from several control cell lines such as pre-B cells, plasmacytoma and mastocytoma cells, did not produce PCR products using primers from the TCR gene.
- TCR gene derived rnRNAs that encode truncated versions of the TCR consisting of the constant (C) domain, which is identical to that of T cell receptor, a joining (J) region, which may be one of several alternatives, and a 5' domain consisting of a nucleotide sequence corresponding to an intronic J sequence (again one of several alternatives) including an in-frame codon for methionine.
- C constant
- J joining
- 5' domain consisting of a nucleotide sequence corresponding to an intronic J sequence (again one of several alternatives) including an in-frame codon for methionine.
- This mRNA lacks V region sequences.
- One of such molecules, namely a new version of a TCR ⁇ 2.6, is shown herein to exist in mesenchymal cells and to encode a cell surface mesenchymal protein.
- the expression or lack of expression of the mesenchymal TCR seems to control mesenchymal cell growth.
- the invention therefore further relates to the use of the cDNA and antisense molecules of the invention derived from mesenchymal TCR mRNAs for expression in cells and tissues for the purpose of modulating stromal/mesenchymal cell growth.
- the cDNA or antisense molecule is inserted in appropriate vectors such as, but not limited to, the retroviral vectors DC Al and DCMm that have been used in clinical trials in gene therapy (Bordignon et al., 1995).
- the vector containing the cDNA or the antisense molecule under the control of a suitable promoter such as that cDNA's own promoter, will be used to infect or transfect suitable mammalian, preferably human, most preferably the patient's autologous mesenchymal cells.
- the genetically modified mesenchymal cells are then administered to a patient in need thereof by an appropriate route and are expressed in the desired site or tissue.
- the complete or partial cDNA of an undesirable gene in accordance with the present invention is inserted into an expression vector comprising a promoter.
- the 3' end of the cDNA is thereby inserted adjacent to the 3' end of the promoter, with the 5' end of the cDNA being separated from the 3' end of the promoter by said cDNA.
- an antisense RNA is therefore produced which is incapable of coding for the protein.
- the presence of antisense RNA in the cell reduces the expression of the cellular (genomic) copy of the undesirable gene.
- the complete cDNA may be used.
- a fragment thereof may be used, which is preferably between about 9 and 1,000 nucleotides in length, more preferably between 15 and 500 nucleotides, and most preferably between 30 and 150 nucleotides.
- the fragment is preferably corresponding to a region within the 5' half of the cDNA, more preferably the 5' region comprising the 5' untranslated region and/or the first exon region, and most preferably comprising the ATG translation start site.
- the fragment may correspond to DNA sequence of the 5' untranslated region only.
- a synthetic oligonucleotide may be used as antisense oligonucleotide.
- the oligonucleotide is preferably a DNA oligonucleotide.
- the length of the antisense oligonucleotide is preferably between 9 and 150, more preferably between 12 and 60, and most preferably between 15 and 50 nucleotides.
- Suitable antisense oligonucleotides that inhibit the production of the protein of the present invention from its encoding mRNA can be readily determined with only routine experimentation through the use of a series of overlapping oligonucleotides similar to a "gene walking" technique that is well-known in the art.
- Such a “walking” technique as well known in the art of antisense development can be done with synthetic oligonucleotides to walk along the entire length of the sequence complementary to the mRNA in segments on the order of 9 to 150 nucleotides in length.
- This "gene walking” technique will identify the oligonucleotides that are complementary to accessible regions on the target mRNA and exert inhibitory antisense activity.
- an oligonucleotide based on the coding sequence of a protein capable of binding to an undesirable gene or the protein encoded thereby can be designed using Oligo 4.0 (National Biosciences, Inc.).
- Antisense molecules may also be designed to inhibit translation of an mRNA into a polypeptide by preparing an antisense which will bind in the region spanning approximately -10 to +10 nucleotides at the 5' end of the coding sequence. Modifications of oligonucleotides that enhance desired properties are generally used when designing antisense oligonucleotides.
- phosphorothioate bonds are used instead of the phosphoester bonds that naturally occur in DNA, mainly because such phosphorothioate oligonucleotides are less prone to degradation by cellular enzymes.
- 2'-methoxyribonucleotide modifications in 60% of the oligonucleotide is used.
- Such modified oligonucleotides are capable of eliciting an antisense effect comparable to the effect observed with phosphorothioate oligonucleotides .
- the preferred antisense oligonucleotide of the present invention has a mixed phosphodiester-phosphorothioate backbone.
- 2'- methoxyribonucleotide modifications in about 30% to 80%, more preferably about 60%, of the oligonucleotide are used.
- antisense oligonucleotides or antisense RNA may be used.
- the length of the antisense RNA is preferably from about 9 to about 3,000 nucleotides, more preferably from about 20 to about 1,000 nucleotides, most preferably from about 50 to about 500 nucleotides.
- the antisense oligonucleotides of the present invention must travel across cell membranes.
- antisense oligonucleotides have the ability to cross cell membranes, apparently by uptake via specific receptors.
- the antisense oligonucleotides are single-stranded molecules, they are to a degree hydrophobic, which enhances passive diffusion through membranes.
- Modifications may be introduced to an antisense oligonucleotide to improve its ability to cross membranes.
- the oligonucleotide molecule may be linked to a group which includes a partially unsaturated aliphatic hydrocarbon chain and one or more polar or charged groups such as carboxylic acid groups, ester groups, and alcohol groups.
- oligonucleotides may be linked to peptide structures, which are preferably membranotropic peptides. Such modified oligonucleotides penetrate membranes more easily, which is critical for their function and may, therefore, significantly enhance their activity.
- the present invention provides proteins encoded by the truncated TCR genes, peptides derived therefrom and antisense DNA molecules based on the TCR transcripts.
- a therapeutic or research-associated use of these tools necessitates their introduction into cells of a living organism or into cultured cells.
- the same principle namely, derivatization with lipophilic structures, may also be used in creating peptides and proteins with enhanced membrane permeability.
- the sequence of a known membranotropic peptide may be added to the sequence of the peptide or protein.
- the peptide or protein may be derivatized by partly lipophilic structures such as the above-noted hydrocarbon chains, which are substituted with at least one polar or charged group.
- lauroyl derivatives of peptides have been described in the art.
- Further modifications of peptides and proteins include the oxidation of methionine residues to thereby create sulfoxide groups and derivatives wherein the relatively hydrophobic peptide bond is replaced by its ketomethylene isoester (COCH 2 ) have been described. It is known to those of skill in the art of protein and peptide chemistry these and other modifications enhance membrane permeability.
- Another way of enhancing membrane permeability is to make use of receptors, such as virus receptors, on cell surfaces in order to induce cellular uptake of the peptide or protein.
- This mechanism is used frequently by viruses, which bind specifically to certain cell surface molecules. Upon binding, the cell takes the virus up into its interior.
- the cell surface molecule is called a virus receptor.
- the integrin molecules CAR and AdV have been described as virus receptors for Adeno virus.
- the CD4, GPR1, GPR15, and STRL33 molecules have been identified as receptors/ coreceptors for HTV.
- peptides, proteins or oligonucleotides By conjugating peptides, proteins or oligonucleotides to molecules that are known to bind to cell surface receptors, the membrane permeability of said peptides, proteins or oligonucleotides will be enhanced.
- suitable groups for forming conjugates are sugars, vitamins, hormones, cytokines, transferrin, asialoglycoprotem, and the like molecules.
- Low et al U.S. Patent 5,108,921 describes the use of these molecules for the purpose of enhancing membrane permeability of peptides, proteins and oligonucleotides, and the preparation of said conjugates.
- Low and coworkers further teach that molecules such as folate or biotin may be used to target the conjugate to a multitude of cells in an organism, because of the abundant and nonspecific expression of the receptors for these molecules.
- cell surface proteins for enhancing membrane permeability of a peptide, protein or oligonucleotide of the invention may also be used in targeting the peptide, protein or oligonucleotide of the present invention to certain cell types or tissues. For instance, if it is desired to target neural cells, it is preferable to use a cell surface protein that is expressed more abundantly on the surface of those cells.
- the protein, peptide or oligonucleotide of the invention may therefore, using the above-described conjugation techniques, be targeted to mesenchymal cells.
- the TCR variant gene could be inserted into mesenchymal cells as a form of gene therapy.
- local application of the cells containing the cDNA molecule can be used to induce mesenchymal cell growth thus enhancing the wound healing process
- mesenchymal cells of the tumor can be transfected with the antisense cDNA and then be used for treatment of localized solid tumors, to achieve regression of the tumor mesenchyme and subsequent regression of the tumor.
- the proteins encoded by the mRNAs of the invention are cell surface receptors of mesenchymal cells and may probably interact with ligands presented by neighboring hemopoietic or non-hemopoietic cells. Thus, in bound or soluble form, these proteins or the peptides derived therefrom, may have modulatory effects on cells that bear said ligands.
- the present invention also comprehends antibodies specific for the proteins encoded by the truncated TCR transcripts which is part of the present invention as discussed above.
- the proteins and peptides of the invention may be used as immunogens for production of antibodies that may be used as markers of mesenchymal cells. Such an antibody may be used for diagnostic purposes to identify the presence of any such naturally occurring proteins.
- Such antibody may be a polyclonal antibody or a monoclonal antibody or any other molecule that incorporates the antigen-binding portion of a monoclonal antibody specific for such a protein.
- Such other molecules may be a single-chain antibody, a humanized antibody, an F(ab) or F(ab') 2 fragment, a chimeric antibody, an antibody to which is attached a label, such as fluorescent or radioactive label, or an immunotoxin in which a toxic molecule is bound to the antigen binding portion of the antibody.
- a label such as fluorescent or radioactive label
- an immunotoxin in which a toxic molecule is bound to the antigen binding portion of the antibody.
- the examples are intended to be non-limiting. However, as long as such a molecule includes the antigen-binding portion of the antibody, it will be expected to bind to the protein and, thus, can be used for the same diagnostic purposes for which a monoclonal antibody can be used.
- compositions are for use by injection, topical administration, or oral uptake.
- Preferred uses of the pharmaceutical compositions of the invention by injection are subcutaneous injection, intravenous injection, and intramuscular injection. Less convenient routes of administration may include intraperitoneal, intradural, intra-thecal administration or infra-arterial administration when required.
- the pharmaceutical composition of the invention generally comprises a buffering agent, an agent which adjusts the osmolarity thereof, and optionally, one or more carriers, excipients and/or additives as known in the art, e.g., for the purposes of adding flavors, colors, lubrication, or the like to the pharmaceutical composition.
- Carriers are well known in the art and may include starch and derivatives thereof, cellulose and derivatives thereof, e.g., microcrystalline cellulose, xanthan gum, and the like.
- Lubricants may include hydrogenated castor oil and the like.
- a preferred buffering agent is phosphate-buffered saline solution (PBS), which solution is also adjusted for osmolarity.
- PBS phosphate-buffered saline solution
- a preferred pharmaceutical formulation is one lacking a carrier. Such formulations are preferably used for administration by injection, including intravenous injection.
- Additives may also be selected to enhance uptake of the antisense oligonucleotide across cell membranes.
- Such agents are generally agents that will enhance cellular uptake of double-stranded DNA molecules.
- certain lipid molecules have been developed for this purpose, including the transfection reagents DOTAP (Boehringer Mannheim), Lipofectin, Lipofectam, and Transfectam, which are available commercially.
- DOTAP Transfection reagents
- Lipofectin Lipofectam
- Transfectam Transfectam
- liposomes e.g., using the above-mentioned transfection reagents, is well known in the art.
- Other methods of obtaining liposomes include the use of Sendai virus or of other viruses.
- the above-mentioned cationic or nonionic lipid agents not only serve to enhance uptake of oligonucleotides into cells, but also improve the stability of oligonucleotides that have been taken up by the cell.
- 293T cell line were grown in Dulbecco's modified Eagles medium (DMEM) supplemented with 10%> fetal calf serum (FCS) (Beth Haemek, Israel), 20mM L- glutamine, 60 ⁇ g/ml penicillin, lOO ⁇ g/ml streptomycin and 50mg/L Kanamycin. Amniotic fluid cells were grown in AMF medium (Biological industries, Beit Haemek, Israel).
- DMEM Dulbecco's modified Eagles medium
- FCS fetal calf serum
- the cDNA of human TCR J ⁇ 2.3-C ⁇ was amplified from cDNA from amniotic fluid cells and from cord blood mononuclear cells using the sense primer 5'CCGGAATTCCATGGGGCTCTCAGCGGTGG and antisense primer 5' CGCGGA TCCCTAGCCTCTGGAATCCTTTCTC and ligated into EcoRI and BamHI digested and calf intestinal alkaline phosphatase-treated pEGFPCl (Clontech, Palo Alto, CA). DNA sequence analysis of the GFP-TCR J ⁇ 2.3-C ⁇ . confirmed the intended reading frame. Proceeding from the N to C terminus, the resulting fusion protein consists of GFP, a linker sequence of 10 amino acids, and TCR J ⁇ 2.3-C ⁇ .
- 293T cells were plated at 70%> confluency in 6 well plates and transfected with 1.6 ⁇ g of GFP-TCR J ⁇ 2.3-C ⁇ construct using the calcium phosphate transfection method.
- Extracts were subjected to 12% SDS-PAGE, blotted and probed with anti-GFP monoclonal antibody JL-8 (Clontech, Palo Alto, CA) and visualized using a secondary antibody, goat anti-mouse-HRP (Sigma). Chemiluminescent signals were generated by incubation with the ECL reagent and the gels were exposed to X-ray film. Cell lines and culture
- the cell lines were cultured by standard procedures such as in DMEM containing 10% FCS or with RPMI 1640 (GIBCO) containing 7% FCS, 2 mM L- glutamine, 5 x 10 "5 M 2-mercaptoethanol and 1 mM sodium pyruvate. Other cell lines were cultured in DMEM containing 10% FCS and D-9 medium containing IL-3 and IX- 4, or cultured in DMEM containing 20% FCS.
- Bone marrow Mouse bone marrow cells were obtained from femur and tibia of 1-2 week old female C57BL/6 mice. Bone marrow cells were removed aseptically by flushing culture medium through the marrow cavity using a 1ml syringe fitted with a 27-gauge needle. 1 x 10 7 cells/ml were seeded in DMEM with 20% FCS (Bio Lab, Israel) and cultured for 4-5 days at 37°C and 5%> C0 2 atmosphere. The plates were washed and covered with fresh culture medium. After 3 weeks, a monolayer was formed. The cells were passaged monthly at a split ratio of 1:10 using 0.5% trypsin (Sigma, St. Louis, MO) containing 0.02% EDTA.
- trypsin Sigma, St. Louis, MO
- Fetal fibroblast Mouse embryos were cut into small pieces in PBS solution and treated with 0.5% trypsin and 0.02% EDTA at 37°C for 15 minutes. The supernatant was collected and treated again with trypsin for 30 minutes. The cell suspension obtained was then washed a few times, resuspended in DMEM containing 10% FCS to a final concentration of 10 6 cells/ml, and cultured for 4-5 days at 37°C and 5% C0 2 atmosphere. When a fibroblast monolayer was formed, it was trypsinized for 5 minutes, and the cells were washed and resuspended as indicated before. This cell suspension (2xl0 5 cells/ml) was cultured again for 4-5 days and then collected.
- Stromal cells were seeded at 1 x 10 s cells/ml on a 96-well round-bottom microplate (Falcon, CA) for 48 hours at 37°C in a humidified atmosphere of 10%> CO 2 in air. The subconfluent cultures were supplemented with the relevant antibodies and incubated for an additional 48 hours. The cells were then pulsed with 1 ⁇ Ci/well of [ 3 H]-thymidine (Nuclear Research Center, Negev, Israel). After 24 hours, the cells were harvested, and the incorporation of tritiated thymidine was determined.
- mAbs monoclonal antibodies
- fluorescein isothiocyanate (FITC)-mAb anti-CD3 ⁇ clone 145-2C11
- low azide no endotoxin or FITC-conjugated hamster anti-mouse TCR ⁇ clone H57-597
- PE phycoerythrin
- Goat anti-human IgM (Kalestab, Denmark), FITC-conjugated goat anti-mouse (Sigma, Israel) and mouse anti- rat IgG (Jackson Immunoresearch Labs, West Grove, PA) served as control antibodies.
- Hybridoma supernatants of anti-TCR ⁇ (clone H57-597) and anti-CD3 ⁇ (clone 145- 2C11) were used for activity assays.
- FITC-conjugated goat anti-hamster IgG was purchased from Jackson Immunoresearch Labs.
- Anti-rabbit FITC Fab fragments was used as a second antibody to detect staining with rabbit polyclonal anti-peptide 1121 and anti-J ⁇ 2.6 [SEQ ID NO: 37] peptide antibodies.
- cells stained with isotype-matched control immunoglobulins were also prepared as negative controls for the surface and the intracellular staining. After washing with PBS, cells were analyzed for fluorescence with a FACScan (Becton Dickinson) with logarithmic intensity scales. In most cases, 5 x 10 3 cells were scored using Lysis II software (Becton Dickinson).
- Hybridization was performed at the same conditions with 1 x 10 6 cpm/ml labeled probe. Filters were washed twice with 1 x SSC, 0.1% SDS at 42°C for 30 minutes and then washed twice with 0.1 x SSC, 0.1% SDS at 55°C for 30 minutes.
- RNAs were reverse transcribed to cDNAs by incubating purified total
- RNA at 37°C for 60 minutes in the presence of MMLV reverse transcriptase The primer pairs used for CD3 ⁇ were as follows: sense primer, 5'- TGCCCTCTAGACAGTGACG-3' ;and antisense primer 5'-
- TCR derived primer pairs were as follows:
- PCR thirty cycles of amplification were carried out using the following conditions for each cycle: denaturation at 94°C for 5 minutes, annealing at 58°C for 2 minutes, and extension at 72°C for 2 minutes.
- 5' and 3' RACE was performed for the cloning of the TCR C ⁇ chain of MBA-13 cells using the Marathon cDNA amplification kit (Clontech, Palo Alto, CA).
- Adaptor ligated cDNA was prepared from MBA-13 mRNA according to manufacturers' directions.
- Hotstart-Touchdown PCR was performed as follows: 94°C for 5 minutes (xl cycle), 94°C for 1 minute and 74°C for 3 minutes (x5 cycles), 94°C for 1 minute and 70°C for 3 minutes (xl5 cycles), 94°C for 1 minute and 68°C for 3 minutes (xlO cycles). Specific primers were used paired to the adaptor primer of the kit.
- the RACE products were cloned into the pGEM-T plasmid (Promega) and transfected into E. coli JM109 cells (Promega). DNA was purified and sequenced using an automated DNA sequencer (Applied Biosystems 373 A, New England Nuclear, Boston, MA).
- Fig. 1 shows the nucleotide sequence of a cDNA that was cloned from the stromal/mesenchymal cell line, MBA-13, that shows a J ⁇ 2.6 flanked by an intronic J
- J int -J ⁇ 2.6-C The J mt -J ⁇ 2.6-C mRNA encodes a putative protein that according to available literature (Irving, 1998) should be capable of being expressed on the cell surface.
- peptide SEQ ID NO:37 was conjugated to KLH and was injected into 2 New Zealand rabbits using Complete Freund's Adjuvant for the first immunization and Incomplete Freund's Adjuvant for additional boosts.
- Pre-immune serum was collected before the first immunization and immune sera were collected after the additional boosts. Reactivity of the serum with the peptide SEQ ID NO: 37 was tested by ELISA.
- the serum was purified on a peptide affinity column (eluted in 0.1 M glycine pH 2.5 and dialyzed to PBS). The purified anti- peptide SEQ ID NO:37 antibody was also tested by ELISA.
- the immunized rabbit serum was processed by isolating the specific antibodies using a column of the immunizing peptide SEQ ID NO:37. These antibodies were then tested for their ability to recognize various cell types: MBA-13 cell strains 1, 2 and 3, mouse embryonic fibroblasts (MEF) and thymus cells as shown in Fig. 2. Whereas thymus cells were not stained (Fig. 2F), as judged by FACS analysis, two strains of the MBA-13 mesenchymal cell lines showed prominent cell surface staining by the polyclonal antibodies (Figs. 2A, 2B). On the other hand, one clone of the MBA-13 cell line was negative (Fig. 2C).
- Example 3 Murine and human truncated TCR ⁇ sequences
- J ⁇ 2.1 can theoretically encode a molecule such as J ⁇ nt -J ⁇ 2.6-C. Indeed, PCR analysis using appropriate primers detected this mRNA in the MBA-13 cell line.
- 9 could theoretically have a composition of intronic J with an in-frame methionine codon.
- Fig. 4 and include: J ⁇ TA31, J ⁇ TA46, J ⁇ New05, J ⁇ S58, J ⁇ New06, J ⁇ New08, J ⁇ LB2A, J ⁇ DKl and J ⁇ TA39.
- Preliminary PCR analysis indicates that at least some of these versions of the ⁇ chain also exist.
- J ⁇ molecules initiated by a methionine from within the exonic coding region (data not shown).
- Example 4 Subcloning of MBA-13 cell line According to the present invention, the uncloned stromal/mesenchymal mouse
- MBA-13 cell line was subdivided into subclones that either express or do not express the molecules of interest, i.e. the J ⁇ nt -J ⁇ 2.6-C protein and mRNA, on the mRNA and antigenic protein levels.
- Fig. 6 shows that all the cells positive for J mt -J ⁇ 2.6-C had a population generation time (doubling time) of 15 hrs or less, which is considered very fast for mesenchymal cells.
- the negative clones showed variable results, all grew much slower and 2 clones had a very slow growth rate with doubling time between 36-38 hrs. It is therefore implied that the expression of the gene of interest correlates with fast growth rate and that lack of expression results in retarded growth.
- TCR ⁇ can operate as a functional receptor and can cause apoptosis in the cells in which it is expressed.
- pT ⁇ augments the function of TCR ⁇ .
- these mesenchymal cells seem to express a pT ⁇ /J mt -J ⁇ 2.6-C complex which is structurally related to a reported TCR complex containing pT ⁇ and an experimentally truncated TCR (Irving, 1998).
- TCR transduction to stromal cell lines derived by the laboratory of the present inventors or obtained from other laboratories, as well as to primary stromal cells from the bone marrow and primary mesenchymal cells from mouse embryos. Specific stromal cell clones, but not all clones tested, expressed TCR ⁇ . Similarly, TCR ⁇ was consistently found in particular stromal cell clones (e.g., the MBA-13 stromal cell line expressed both C ⁇ and C ⁇ , whereas the MBA- 15 stromal cell line did not express C ⁇ but was positive for C ⁇ (Figs. 7A-7C).
- TCR gene expression was not found in B cells, mast cells or liver cells (Figs. 7A-7B).
- Example 6 mRNA expression of TCRC ⁇ , TCRC ⁇ , and CD3 ⁇
- TCR ⁇ mRNA was detected in the MBA-13 stromal cell line and also in primary fetal and bone marrow fibroblast cultures.
- the sizes of the TCR ⁇ transcript corresponded to that found in thymic T cells, whereas the size of the mRNA detected by the TCR ⁇ probe was about 1.1 kb as compared to 1.0 kb and 1.3 kb detected in the thymus.
- this shorter mRNA version was consistently found in different stromal cell lines, as well as in primary mesenchymal cells.
- a 1.0 kb mRNA species has been reported in bone marrow-derived immature precursor T cells. The relationship between the mesenchymal 1.1 kb mRNA species and that found in early bone marrow thymocytes remains to be examined.
- Example 8 Cytometric analysis of a mesenchymal cell surface antigen reactive with an anti-TCR ⁇ antibody
- the expression of the fusion protein, GFP-TCR J ⁇ 2.3-C ⁇ , in 293T transfected cells was determined by Western blot analysis. Each lane was loaded with lysate of 5x10 5 cells. The GFP-TCR J ⁇ 2.3-C ⁇ was detected with anti-GFP monoclonal antibody JL-8 (Fig. 12).
- Example 12 In vivo utility
- compositions of the present invention can be used for treatment of diseases involving modulation of mesenchymal growth.
- treatment of disease is meant prevention or amelioration of the disease or of symptoms associated with the disease, or minimizing subsequent worsening of the disease or of symptoms associated with the disease.
- the diseases and conditions to be treated include conditions in which it is preferable to inhibit mesenchymal growth including: cancer, especially in the case of metastasis to any organ, especially the bone marrow, nonmalignant proliferative diseases of any organ, especially the bone marrow, bone marrow defects resulting in hematological disorders such as anemias or leukemias and autoimmune diseases involving any organ, especially the bone marrow.
- the present invention can be used for treatment of conditions where it is desirable to augment mesenchymal growth including autologous or allogeneic bone marrow transplantation, wound healing and autologous or allogeneic organ transplantation.
- compositions of the present invention will depend on the type of injury, disease or condition being treated.
- treatment of an acute event will necessitate systemic administration of the active composition comparatively rapidly after induction of the injury.
- diminution of chronic degenerative damage will necessitate a sustained dosage regimen.
- Kimoto, Y (1998). Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes, Chromosomes, Cancer 22(1): 83-86.
- TARP a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus.
- Proc Natl Acad Sci USA 97(17): 9437-42 Yoshikai Y, Anatoniou D, Clark SP, Yanagi Y, Sangster R, Van den Elsen P, Terhorst C, Mak TW (1984). Sequence and expression of transcripts of the human T-cell receptor beta-chain genes. Nature 312(5994):521-4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002438775A CA2438775A1 (en) | 2001-02-20 | 2002-02-20 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
JP2002566342A JP2004529624A (en) | 2001-02-20 | 2002-02-20 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
IL15748502A IL157485A0 (en) | 2001-02-20 | 2002-02-20 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
EP02712232A EP1362104A2 (en) | 2001-02-20 | 2002-02-20 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
US10/642,642 US20040259196A1 (en) | 2001-02-20 | 2003-08-19 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14153901A IL141539A0 (en) | 2001-02-20 | 2001-02-20 | Dna molecules and cells transfected therewith |
IL141539 | 2001-02-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/642,642 Continuation US20040259196A1 (en) | 2001-02-20 | 2003-08-19 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002066636A2 true WO2002066636A2 (en) | 2002-08-29 |
WO2002066636A3 WO2002066636A3 (en) | 2002-11-28 |
Family
ID=11075149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2002/000130 WO2002066636A2 (en) | 2001-02-20 | 2002-02-20 | T cell receptor variants expressed in mesenchymal cells and uses thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040259196A1 (en) |
EP (1) | EP1362104A2 (en) |
JP (1) | JP2004529624A (en) |
CA (1) | CA2438775A1 (en) |
IL (1) | IL141539A0 (en) |
WO (1) | WO2002066636A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2894164A1 (en) | 2006-07-05 | 2015-07-15 | F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H | Method for engineering T-cell receptors |
US9651559B2 (en) | 2007-06-26 | 2017-05-16 | F-star Biotechnologische Forschungs— und Entwicklungsges.m.b.H | Display of binding agents |
US9856311B2 (en) | 2005-01-05 | 2018-01-02 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
US10125197B2 (en) | 2008-05-02 | 2018-11-13 | F-Star Biotechnologische Forschungs-Und Entwicklungsges.M.B.H | Cytotoxic immunoglobulin |
WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
US11827720B2 (en) | 2006-07-05 | 2023-11-28 | F-Star Therapeutics Limited | Multivalent immunoglobulins |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
CN104395344B (en) | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | Anti- B7-H6 antibody, fusion protein and its application method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137081A1 (en) * | 2001-01-08 | 2002-09-26 | Olga Bandman | Genes differentially expressed in vascular tissue activation |
-
2001
- 2001-02-20 IL IL14153901A patent/IL141539A0/en unknown
-
2002
- 2002-02-20 JP JP2002566342A patent/JP2004529624A/en active Pending
- 2002-02-20 EP EP02712232A patent/EP1362104A2/en not_active Withdrawn
- 2002-02-20 WO PCT/IL2002/000130 patent/WO2002066636A2/en active Search and Examination
- 2002-02-20 CA CA002438775A patent/CA2438775A1/en not_active Abandoned
-
2003
- 2003-08-19 US US10/642,642 patent/US20040259196A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
BARDA-SAAD MIRA ET AL: "The mesenchyme expresses T cell receptor mRNAs: relevance to cell growth control." ONCOGENE. ENGLAND 27 MAR 2002, vol. 21, no. 13, 27 March 2002 (2002-03-27), pages 2029-2036, XP001088472 ISSN: 0950-9232 * |
ESSAND M ET AL: "High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, August 1999 (1999-08), pages 9287-9292, XP002151630 ISSN: 0027-8424 cited in the application * |
WOLFGANG CURT D ET AL: "TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 17, 15 August 2000 (2000-08-15), pages 9437-9442, XP002207096 August 15, 2000 ISSN: 0027-8424 cited in the application * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9856311B2 (en) | 2005-01-05 | 2018-01-02 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
US10385118B2 (en) | 2005-01-05 | 2019-08-20 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
EP2894164A1 (en) | 2006-07-05 | 2015-07-15 | F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H | Method for engineering T-cell receptors |
US11827720B2 (en) | 2006-07-05 | 2023-11-28 | F-Star Therapeutics Limited | Multivalent immunoglobulins |
US9651559B2 (en) | 2007-06-26 | 2017-05-16 | F-star Biotechnologische Forschungs— und Entwicklungsges.m.b.H | Display of binding agents |
US10125197B2 (en) | 2008-05-02 | 2018-11-13 | F-Star Biotechnologische Forschungs-Und Entwicklungsges.M.B.H | Cytotoxic immunoglobulin |
WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2438775A1 (en) | 2002-08-29 |
JP2004529624A (en) | 2004-09-30 |
EP1362104A2 (en) | 2003-11-19 |
WO2002066636A3 (en) | 2002-11-28 |
US20040259196A1 (en) | 2004-12-23 |
IL141539A0 (en) | 2002-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230025572A1 (en) | High avidity antigen recognizing constructs | |
AU2017373815B2 (en) | Novel T cell receptors and immune therapy using the same | |
CN107960056B (en) | Occludin-18.2 specific immunoreceptor and T cell epitopes | |
AU2021203099A1 (en) | Novel t cell receptors and immune therapy using the same | |
JP6133209B2 (en) | Anti-SSX-2T cell receptor and related materials and methods of use | |
JP7100177B2 (en) | Thymic stromal lymphocyte neoplastic factor receptor-specific chimeric antigen receptor and method of using it | |
JP2020519298A (en) | Bicistronic chimeric antigen receptors and their use | |
US9469684B2 (en) | Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen | |
TW200823235A (en) | Prophylactic and therapeutic agent for cancers | |
JP7475088B2 (en) | Immunocompetent cells expressing cell surface molecules that specifically recognize human mesothelin, IL-7, and CCL19 | |
US20040259196A1 (en) | T cell receptor variants expressed in mesenchymal cells and uses thereof | |
US20220064256A1 (en) | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies | |
Devaux et al. | Generation of monoclonal antibodies against soluble human T cell receptor polypeptides | |
WO2022063194A1 (en) | Cpsg4-targeting humanized chimeric antigen receptor, immune effector cell expressing chimeric antigen receptor, and applications thereof | |
WO2002070552A2 (en) | POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF | |
US20040110218A1 (en) | BMOG, a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for immunomodulatory purposes | |
AU2002232108A1 (en) | T cell receptor variants expressed in mesenchymal cells and uses thereof | |
JP2007523895A (en) | Method of inhibiting Bright function as a treatment for excessive immunoglobulin production | |
KR20240046103A (en) | Anti-IGSF1 antibodies and uses thereof | |
US20040171111A1 (en) | Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof | |
EP4079753A1 (en) | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes | |
KR102381854B1 (en) | T cell receptors and immunotherapy using them | |
US20040101931A1 (en) | Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof | |
AU7208600A (en) | B7-2:CTL A4/CD 28 counter receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002232108 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 157485 Country of ref document: IL Ref document number: 10642642 Country of ref document: US Ref document number: 2002566342 Country of ref document: JP Ref document number: 2438775 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002712232 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002712232 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002712232 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |